Status | Study |
Not yet recruiting |
Study Name: Pasireotide in Hyperinsulinemic Hypoglycemia Condition: Congenital Hyperinsulinism Insulinoma Date: 2017-02-09 Interventions: Drug: Pasireotide 0.6Mg Solution for Injection |
Recruiting |
Study Name: 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Condition: Congenital Hyperinsulinism Neuroblastoma Date: 2017-02-01 Interventions: Drug: 18F-DOPA 18F-DOPA intravenous injection single dose |
Recruiting |
Study Name: CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2016-10-14 Interventions: Drug: Glucagon Room-temperatur |
Available |
Study Name: Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia Condition: Congenital Hyperinsulinism Date: 2016-07-13 Interventions: Drug: Pasireotide Other Names: Signifor SOM230 |
Completed |
Study Name: A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2015-10-26 Interventions: Drug: Cohort 1 XOMA 358 single |
Recruiting |
Study Name: 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis Condition: Insulinoma Nesidioblastosis Date: 2015-09-24 Interventions: Drug: 68Ga-NOTA-exendin-4 68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans |
Available |
Study Name: Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia Condition: Hyperinsulinemic Hypoglycemia, Persistent Congenital Hyperinsulinism Date: 2015-08-24 Interventions: Drug: 18 F-DOPA Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed aft |
Recruiting |
Study Name: Sirolimus for the Treatment of Hyperinsulinism Condition: Hyperinsulinism Date: 2015-08-12 Interventions: Drug: Sirolimus Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated |
Completed |
Study Name: Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism Condition: Non-focal Congenital Hyperinsulinism Date: 2014-03-28 Interventions: Procedure: restrictive pancreatic resection Restrictive, spleen-preserving resection of the pancreatic t |
Recruiting |
Study Name: Fluorodopa F 18 in Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2013-12-20 Interventions: Drug: Fluorodopa F 18 A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intrave |